Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Network modeling predicts how DYRK1A inhibition promotes cardiomyocyte cycling after ischemia/reperfusion injury
Bryce C. Murillo, Alexander Young, Kaitlyn L. Wintruba, Alexander J. Eichert, Klara Siejda, Dennon Hoernig, Leigh A. Bradley, Bryana N. Harris, Catherine Zhao, Michelle Wu, Emmanuel Deau, Mattias F. Lindberg, Laurent Meijer, Jeffrey J. Saucerman, Matthew J. Wolf
Bryce C. Murillo, Alexander Young, Kaitlyn L. Wintruba, Alexander J. Eichert, Klara Siejda, Dennon Hoernig, Leigh A. Bradley, Bryana N. Harris, Catherine Zhao, Michelle Wu, Emmanuel Deau, Mattias F. Lindberg, Laurent Meijer, Jeffrey J. Saucerman, Matthew J. Wolf
View: Text | PDF
Research Article Cardiology Cell biology

Network modeling predicts how DYRK1A inhibition promotes cardiomyocyte cycling after ischemia/reperfusion injury

  • Text
  • PDF
Abstract

The adult mammalian heart has a limited ability to regenerate lost myocardium following myocardial infarction (MI), largely due to the poor proliferative capacity of cardiomyocytes (CMs). Dual-specificity tyrosine phosphorylation–regulated kinase 1A (DYRK1A) is a known regulator of cell quiescence, though the mechanisms underlying its function remain unclear. Previous studies have shown that pharmacological inhibition of DYRK1A using harmine induces CM cell cycle reentry after ischemia/reperfusion (I/R) MI. Here, we developed a computational network model of DYRK1A-mediated regulation of the cell cycle, which predicts how DYRK1A inhibition promotes CM reentry. To validate these predictions, we tested selective DYRK1A inhibitors and observed robust induction of cell cycle activity in neonatal rat cardiomyocytes (NRCMs). Integrating our network model with bulk RNA sequencing data from DYRK1A inhibitor–treated NRCMs, we identified E2F1 as a key transcriptional driver of cell cycle gene expression. Finally, we demonstrate that both pharmacological and post-developmental inhibition of DYRK1A enhances heart function and increases CM cycling following I/R MI. Our findings suggest that functional recovery induced by small-molecule inhibitors of DYRK1A is mediated by the induction of cycling CMs.

Authors

Bryce C. Murillo, Alexander Young, Kaitlyn L. Wintruba, Alexander J. Eichert, Klara Siejda, Dennon Hoernig, Leigh A. Bradley, Bryana N. Harris, Catherine Zhao, Michelle Wu, Emmanuel Deau, Mattias F. Lindberg, Laurent Meijer, Jeffrey J. Saucerman, Matthew J. Wolf

×

Figure 8

Ablation of cycling CMs attenuates beneficial effects of LCTB-92 treatment.

Options: View larger image (or click on image) Download as PowerPoint
Ablation of cycling CMs attenuates beneficial effects of LCTB-92 treatme...
(A) Schematic of treatment of 12-week-old αDKRC:RLTG/DTA or +:RLTG/DTA mice with LCTB-92 (10 mg/kg) for 10 days following I/R MI. (B and C) Cardiac function measurements of αDKRC:RLTG/DTA or control (+:RLTG/DTA) mice treated with LCTB-92 or isomeric control after I/R MI, showing absolute (percent) (B) and percent change (from baseline) LVEF (C) 2 and 4 weeks after MI. N = 10 animals per group. Values are mean ± SD. P values were calculated using 2-way ANOVA followed by Bonferroni’s multiple-comparison test. *P = 0.005 for each value compared with baseline; ΔP = 0.001 for each value compared with baseline; ǂP = 0.05 for αDKRC:RLTG/DTA vs. control. (D) Representative echocardiography parasternal long-axis views of αDKRC:RLTG/DTA or control (+:RLTG/DTA) mice treated with LCTB-92 at 4 weeks after I/R MI. (E and F) Average infarct size (percent) across whole heart sections from αDKRC:RLTG/DTA or control (+:RLTG/DTA) hearts treated with LCTB-92 at 4 weeks after MI (E) with representative images (F). Values are mean ± SD. Two-sample t test was performed for E.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts